

We report on the effectiveness of our material nonfinancial topics by monitoring key performance indicators (KPI). KPIs are included in the evaluation sections of the material topics in our Group Non-financial Report. Additional KPIs are provided in our Sustainability Report as well as on our corporate website. This overview is currently only available in English.

[Fresenius Group Annual Report 2021](#)

[Fresenius Group Sustainability Report 2021](#)

## 1. Quality

Patients treated	2021	2020	2019	2018	2017
in dialysis centers	345,425	346,553	345,096	333,331	320,960
in hospitals and outpatient centers of Fresenius Helios	22,567,138	20,189,521	20,962,664	18,639,511	16,916,922

Health care facilities	2021	2020	2019	2018	2017
Dialysis centers worldwide	4,171	4,092	3,994	3,928	3,752
Acute care clinics	146	141	134	130	133
<i>thereof Germany</i>	90	89	83	83	88
<i>thereof Spain and Latin America</i>	56	52	51	47	45

Number of Beds (Acute care)	2021	2020	2019	2018	2017
Clinics Germany	29,955	29,451	28,380	28,802	29,438
Clinics Spain and Latin America	8,174	7,936	7,288	7,019	6,652

Quality Management in Patient Care	2021	2020	2019	2018	2017
<b>Fresenius Medical Care</b>					
Global hospitalization rate per patient in days	10.7	n.a.	n.a.	n.a.	n.a.
Net Promoter Score (NPS)	71	67	n.a.	n.a.	n.a.
<b>Fresenius Helios, Germany</b>					
Average length of stay	5.7	5.7	5.8	5.9	6.2
Hospitals covered by Quality Standard GIQI, Germany	100%	100%	100%	100%	100%
GIQI targets achieved	91%	89%	96%	89%	98%
Peer Reviews	7	8	60	55	69
Patient safety events recorded	85	105	n.a.	n.a.	n.a.
Allegations of treatment errors (justified or unjustified)	768	958	1,082	1,051	1,056
Average treatment errors per 1,000 patients <sup>1</sup>	0.8	0.9	0.9	0.9	0.9
CIRS reports (Critical Incident Reporting System)	576	485	n.a.	n.a.	n.a.

	2021	2020	2019	2018	2017
<b>Fresenius Helios, Spain</b>					
Hospitals covered by					
Quality Standard ISO 9001, Spain	100%	100%	100%	100%	100%
Net Promoter Score, Spain	50	54	55	n.a.	n.a.
Total Reports (NPS), Spain	534,930	361,800	426,061	n.a.	n.a.
Peer Reviews	4	2	8	n.a.	n.a.
Patient Safety Incidents	8,480	4,897	4,350	n.a.	n.a.
<b>Fresenius Vamed</b>					
Entities covered by					
Quality Standard ISO 9001	74%	n.a.	n.a.	n.a.	n.a.

<sup>1</sup> Average allegation of treatment error (justified or unjustified) per 1,000 patients; incl. all specialties and all stages of treatment, from patient information, diagnostics, surgery, and therapy and to aftercare.

<b>Quality Management in Production</b>					
	2021	2020	2019	2018	2017
<b>Fresenius Medical Care</b>					
Number of production sites worldwide					
	42	44	45	42	41
Operations covered by					
quality management systems (%) <sup>1</sup>	98	98	n.a.	n.a.	n.a.
Audit Score <sup>2</sup>	0.1	0.2	0.2	0.3	n.a.
<b>Fresenius Kabi</b>					
Entities covered by					
quality management systems	104	115	118	115	n.a.
certified by ISO 9001, in % <sup>3</sup>	78	n.a.	n.a.	n.a.	n.a.
Audit Score <sup>4</sup>	1.9	1.3	1.5	1.8	n.a.
Internal audits	58	42	60	>70	n.a.
External audits and inspections	94	59	64	>90	n.a.

<sup>1</sup> FME: Includes ISO 9001/13485, Good Manufacturing Practice (GMP)/ Current Good Manufacturing Practice (cGMP), and Medical Device Single Audit Program (MDSAP).

<sup>2</sup> FME: The audit score measures our performance in certification audits and indicates the ratio of major and critical findings to the number of external audits.

<sup>3</sup> external reporting started in 2021; coverage target 100% of relevant entities, variation due to organizational changes, e.g., opening, closing of locations; %-coverage subject based on entities for which the standard is of relevance.

<sup>4</sup> For the calculation of the audit and inspection score, Fresenius Kabi takes into account all information on findings from audits and inspections received by the company before December 31 of the reporting year.

## 2. Innovation and Digitalization

<b>Clinical Study Management</b>					
	2021	2020	2019	2018	2017
<b>Fresenius Helios, Germany</b>					
Clinical studies, total					
	424	468	n.a.	n.a.	n.a.
Helios as initiator	143	133	n.a.	n.a.	n.a.
Academically managed studies, publicly funded <sup>1</sup>	140	163	n.a.	n.a.	n.a.

	2021	2020	2019	2018	2017
<i>Academically-led or publicly-sponsored studies with industry support; trial drugs typically provided</i> <sup>2</sup>	30	47	n.a.	n.a.	n.a.
<i>Industry-sponsored studies</i> <sup>3</sup>	111	125	n.a.	n.a.	n.a.

#### Fresenius Helios, Spain

Clinical studies, total	1,230	n.a.	n.a.	n.a.	n.a.
Observation studies	> 370	n.a.	n.a.	n.a.	n.a.
Research initiatives	> 600	n.a.	n.a.	n.a.	n.a.

<sup>1</sup> The majority of these studies are led by universities, mostly with public research funding.

<sup>2</sup> The majority of these studies are led by universities/professional societies, but are supported by drug/medical devices manufacturers, which usually extends to the provision of the drugs/medical devices.

<sup>3</sup> The majority of these studies are supported by the pharmaceutical industry; less than 20% are medical device manufacturers.

Research and Development	2021	2020	2019	2018	2017
R&D expenses, € in millions <sup>1</sup>	818	748	677	649	538
<i>as % of product sales</i> <sup>1, 2</sup>	7.5	7.2	6.8	6.7	5.7
R&D employees	3,656	3,565	3,412	3,042	2,772

<sup>1</sup> 2021: Before expenses related to the Fresenius cost and efficiency program and revaluations of contingent biosimilars purchase price liabilities  
2020, 2019, and 2018: Revaluations of biosimilars contingent purchase price liabilities

<sup>2</sup> 2021, 2019, and 2018 excluding impairment losses from capitalized in-process R & D activities

### 3. Employees

Headcount, FTE	2021	2020	2019	2018	2017
Headcount, total	316,078	311,269	294,134	276,750	273,249
Headcount, by function					
<i>Production</i>	42,841	41,995	42,572	41,100	40,189
<i>Service</i>	224,944	222,427	208,070	194,868	194,117
<i>Administration</i>	31,072	30,173	28,157	26,112	25,015
<i>Sales and marketing</i>	13,565	13,109	11,923	11,628	11,156
<i>Research and development</i>	3,656	3,565	3,412	3,042	2,772
Headcount, by business segment					
<i>Fresenius Medical Care</i>	130,251	133,129	128,300	120,328	121,245
<i>Fresenius Kabi</i>	41,397	40,519	39,627	37,843	36,380
<i>Fresenius Helios</i>	123,484	116,952	106,377	100,144	105,927
<i>Fresenius Vamed</i>	19,721	19,414	18,592	17,299	8,667
<i>Corporate / Other</i>	1,225	1,255	1,238	1,136	1,030
Headcount, by region					
<i>Europe</i>	180,122	174,835	165,862	158,939	154,172
<i>thereof Germany</i>	98,754	96,915	91,014	88,086	86,613
<i>Europe excl. Germany</i>	81,368	77,920	74,848	70,853	67,559
<i>North America</i>	76,740	75,837	74,894	72,672	75,083
<i>Asia-Pacific</i>	27,145	27,805	27,457	25,575	24,381
<i>Latin America</i>	30,192	30,871	23,998	17,610	17,709
<i>Africa</i>	1,879	1,921	1,923	1,954	1,904

	2021	2020	2019	2018	2017
FTE, total	281,011	277,822	262,904	246,329	243,913
<i>Fresenius Medical Care</i>	122,909	125,364	120,659	112,658	114,000
<i>Fresenius Kabi</i>	39,579	39,032	38,264	36,423	34,923
<i>Fresenius Helios</i>	101,652	96,899	88,057	82,522	85,577
<i>Fresenius Vamed</i>	15,730	15,364	14,770	13,665	7,215
<i>Corporate / Other</i>	1,141	1,166	1,154	1,060	969

<b>Staff recruiting and loyalty</b>	2021	2020	2019	2018	2017
-------------------------------------	------	------	------	------	------

New hires, % <sup>1,2</sup>					
<i>Fresenius Medical Care</i>	23.7	23.1	24.7	21.7	n.a.
<i>Fresenius Kabi</i>	17.1	13.5	17.1	16.9	19.8
<i>Helios Germany</i>	18.8	14.3	15.4	16.0	19.8
<i>Helios Spain</i>	29.0	25.5	20.1	27.6	n.a.
<i>Fresenius Vamed</i>	18.4	18.4	17.8	22.5	11.0
<i>Corporate / Other</i>	11.0	6.1	11.2	12.5	9.7

New hires, in % <sup>4</sup> by region	22.0	n.a.	n.a.	n.a.	n.a.
<i>Europe</i>	19.4	n.a.	n.a.	n.a.	n.a.
<i>North America</i>	22.8	n.a.	n.a.	n.a.	n.a.
<i>Asia-Pacific</i>	20.4	n.a.	n.a.	n.a.	n.a.
<i>Latin America</i>	37.3	n.a.	n.a.	n.a.	n.a.
<i>Africa</i>	13.9	n.a.	n.a.	n.a.	n.a.

Voluntary turnover, % <sup>2,3</sup>	12.8	9.8	11.0	9.8	9.9
<i>Fresenius Medical Care</i>	16.5	11.9	14.3	13.2	12.2
<i>Fresenius Kabi</i>	11.3	7.1	9.2	9.4	11.3
<i>Helios Germany</i>	9.5	8.3	9.1	6.9	6.0
<i>Helios Spain</i>	11.0	9.8	7.6	3.8	n.a.
<i>Fresenius Vamed</i>	9.3	7.8	7.6	9.5	8.0
<i>Corporate / Other</i>	3.5	1.7	3.5	3.8	2.7

Voluntary turnover, in % by region					
<i>Europe</i>	9.3	n.a.	n.a.	n.a.	n.a.
<i>North America</i>	14.4	n.a.	n.a.	n.a.	n.a.
<i>Asia-Pacific</i>	16.0	n.a.	n.a.	n.a.	n.a.
<i>Latin America</i>	26.6	n.a.	n.a.	n.a.	n.a.
<i>Africa</i>	9.4	n.a.	n.a.	n.a.	n.a.

Average length of service, years <sup>2</sup>	8.3	8.2	8.1	8.2	8.1
<i>Fresenius Medical Care</i>	7.6	7.3	6.8	7.1	7.0
<i>Fresenius Kabi</i>	7.9	7.9	8.6	7.5	7.4
<i>Helios Germany</i>	10.3	10.3	10.6	10.8	10.5
<i>Helios Spain</i>	7.7	8.0	8.4	8.2	n.a.
<i>Fresenius Vamed</i>	7.8	7.7	6.9	7.8	6.1
<i>Corporate / Other</i>	7.8	7.5	7.3	7.3	7.6

Average length of service (years), by region					
<i>Europe</i>	7.8	n.a.	n.a.	n.a.	n.a.
<i>North America</i>	7.5	n.a.	n.a.	n.a.	n.a.
<i>Asia-Pacific</i>	6.3	n.a.	n.a.	n.a.	n.a.

	2021	2020	2019	2018	2017
Latin America	6.6	n.a.	n.a.	n.a.	n.a.
Africa	7.3	n.a.	n.a.	n.a.	n.a.

<sup>1</sup> Calculated as the number of external hires in a business segment within the reporting period, relative to the number of employees at year-end.

<sup>2</sup> Fresenius Medical Care's 2017 data reflects country data representing 96% of all employees. Helios Germany's data for 2017 includes the post-acute care business in Germany. Fresenius Vamed's data for 2017 also includes temporary staff and, as of 2018, the German post-acute care business transferred from Fresenius Helios to Fresenius Vamed. The data from Helios Spain contains the hospitals in Latin America as of 2020. Data does not include the recently acquired company Eugin, yet.

<sup>3</sup> Calculated as the number of employees who left the organization voluntarily in relation to the number of employees at the end of the year.

<sup>4</sup> Calculated as the consolidated number of external hires in a region by the business segments within the reporting period, relative to the number of employees of the business segments in a region at year-end.

Diversity, Equity and Inclusion	2021	2020	2019	2018	2017
Headcount, female employees	216,592	212,528	200,505	188,873	187,117
Female employees in the business segments, %	69	68	68	68	68
Fresenius Medical Care	69	69	69	69	69
Fresenius Kabi	51	50	50	50	51
Fresenius Helios	74	75	75	75	76
Fresenius Vamed	62	62	63	64	56
Corporate / Other	40	38	39	39	39
Share of women in management participating in LTIP	32.6%	31.6%	31.6%	30.3%	30.3%
Employees with disabilities <sup>1</sup>	5,531	5,452	5,171	4,444	4,369
in % of employees <sup>1</sup>	4%	4%	4%	5%	5%

<sup>1</sup> Scope: Total staff Germany, clinics of Fresenius Helios in Spain as of 2019

Nationalities (German entities)	>140	>150	>150	n.a.	n.a.
<b>Age structure (Headcount)</b>					
Below 30 years, in %	19	19	19	18	19
Between 30 and 50 years, in %	55	55	55	55	55
Above 50 years, in %	26	26	26	27	26
Average age (Headcount), years <sup>1</sup>	41.6	41.7	41.0	41.0	41.5
Fresenius Medical Care	42.1	41.7	40.8	40.8	41.7
Fresenius Kabi	39.2	39.9	38.7	38.4	38.5
Helios Germany	42.2	42.2	42.5	42.6	42.7
Helios Spain	40.4	40.5	41.0	40.0	n.a.
Fresenius Vamed	44.3	44.0	41.2	43.6	43.0
Corporate / Other	39.7	39.3	39.1	38.9	39.2

<sup>1</sup> Fresenius Medical Care's 2017 data reflects country data representing 96% of all employees. Helios Germany's data for 2017 includes the post-acute care business in Germany. Fresenius Vamed's data for 2017 also includes temporary staff and, as of 2018, the German post-acute care business transferred from Fresenius Helios to Fresenius Vamed. The data from Helios Spain contains the hospitals in Latin America as of 2020. Data does not include the recently acquired company Eugin, yet.

<b>Working Models</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
<b>Full-time employees <sup>1</sup></b>					
share of men	79%	79%	n.a.	n.a.	n.a.
share of women	59%	59%	n.a.	n.a.	n.a.
Employees working full-time <sup>1</sup>	64%	64%	n.a.	n.a.	n.a.
thereof male	32%	31%	n.a.	n.a.	n.a.
thereof female	68%	69%	n.a.	n.a.	n.a.
<b>Part-time employees <sup>1</sup></b>					
share of men	21%	21%	n.a.	n.a.	n.a.
share of women	41%	41%	n.a.	n.a.	n.a.
Employees working part-time <sup>1</sup>	36%	36%	n.a.	n.a.	n.a.
thereof male	15%	15%	n.a.	n.a.	n.a.
thereof female	85%	85%	n.a.	n.a.	n.a.
<b>Parental leave</b>					
(Germany) of employees total	5%	6%	n.a.	n.a.	n.a.
<i>thereof male</i>	18%	19%	n.a.	n.a.	n.a.
<i>thereof female</i>	82%	81%	n.a.	n.a.	n.a.

<sup>1</sup> 2021: Entities in Germany as well as business segment Fresenius Helios; 2020 only Fresenius Helios

<b>Employee participation and collective bargaining</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
Employees are covered by collective bargaining agreements					
Europe	78%	77%	71%	n.a.	n.a.
Global <sup>1</sup>	50%	n.a.	n.a.	n.a.	n.a.

<sup>1</sup> Based on about 91% of Fresenius Group total employees.

<b>Board Diversity</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
<b>Management Board</b>					
Share of women	14%	14%	14%	14%	14%
members between 30 and 50 years	14%	14%	14%	14%	29%
members over 50 years	86%	86%	86%	86%	71%
Non-Germans	43%	57%	57%	57%	57%
Average tenure (years)	7.9	8.0	8.9	7.9	6.9
<b>Supervisory Board <sup>1</sup></b>					
Share of women	42%	42%	33%	33%	33%
members between 30 and 50 years	17%	17%	8%	8%	17%
members over 50 years	83%	83%	92%	92%	83%
Non-Germans	17%	25%	25%	25%	25%
Average tenure (years)	6.0	6.5	6.6	5.6	5.5

<sup>1</sup> Applies to total board

<b>Labor Cost</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
Personnel expenses					
in total, € million	15,610	15,128	14,355	13,426	13,496
<i>thereof wages and salaries</i>	12,679	12,357	11,651	10,753	10,811

	2021	2020	2019	2018	2017
per average employee (€ thou.)	49.8	49.5	49.5	48.6	50.1
in % of sales	41.6	41.7	40.5	40.4	39.8
Average employee compensation, in € <sup>1</sup>	40,114	39,699	39,611	38,855	39,565

<sup>1</sup> Calculated as total wages and salaries divided by total headcount

## 4. Compliance & Integrity

Compliance	2021	2020	2019	2018	2017
Reports, total	2,119	1,729	n.a.	n.a.	n.a.
<i>thereof business Integrity</i>					
<i>including anti-corruption</i>	105	110	n.a.	n.a.	n.a.
<i>thereof data protection</i>	659	368	n.a.	n.a.	n.a.
<i>thereof Human Resources/workplace</i>	1,040	999	n.a.	n.a.	n.a.
Reports by input channel, %					
<i>Hotline (phone)</i>	29	15	n.a.	n.a.	n.a.
<i>Web-based system</i>	26	22	n.a.	n.a.	n.a.
<i>Email/Letter</i>	17	39	n.a.	n.a.	n.a.
<i>Personal report (incl. direct calls)</i>	5	3	n.a.	n.a.	n.a.
<i>Other</i>	23	21	n.a.	n.a.	n.a.
Tax Compliance					
Effective tax rate by region					
<i>Europe</i>	24.2%	25.5%	23.9%	n.a.	n.a.
<i>North America</i>	21.1%	22.2%	20.1%	n.a.	n.a.
<i>Asia-Pacific</i>	23.4%	18.2%	23.6%	n.a.	n.a.
<i>Latin America</i>	26.4%	-27.5%	57.1%	n.a.	n.a.
<i>Africa</i>	28.0%	-193.8%	63.6%	n.a.	n.a.
<i>Group</i>	22.8%	24.2%	22.6%	n.a.	n.a.

## 5. Environment

Water withdrawal	2021	2020	2019	2018	2017
Group, in million m <sup>3</sup>	56.4	56.2	57.3	56.2	50.1
<i>Fresenius Medical Care</i>	41.4	41.7	43.2	42.1	35.7
<i>Fresenius Kabi</i>	10.1	9.7	9.5	9.7	9.8
<i>Fresenius Helios</i>	4.0	4.1	3.8	3.7	4.3
<i>Fresenius Vamed</i>	0.8	0.8	0.7	0.7	0.3
Group by source, in million m <sup>3</sup>					
<i>Surface water</i>	0.7	0.7	0.7	0.7	0.7
<i>Groundwater</i>	4.4	4.4	4.3	4.6	4.2
<i>Seawater</i>	0.0	0.0	0.0	0.0	0.0
<i>Produced water</i>	0.0	0.0	0.0	0.0	0.0
<i>Third-party water (municipal supply)</i>	51.2	51.2	52.2	50.9	45.2
<b>Fresenius Group<sup>1</sup> relative water withdrawal</b>					
Water withdrawal / € 1 million sales	1,502	1,549	1,612	1,676	1,487
Water withdrawal / FTE	201.8	203.1	218.7	228.2	208.4
Water withdrawal / hospital bed <sup>2</sup>	106	109	106	104	119

<sup>1</sup> Fresenius Medical Care figures include water withdrawal at production sites, as well as water withdrawal at dialysis centers. The data from Fresenius Helios encompasses as of 2018 all hospitals in Spain and the clinics in Latin America as of 2020. Fresenius Vamed's data includes all fully consolidated health care facilities and service entities, and, as of 2018, the German post-acute care business transferred from Fresenius Helios to Fresenius Vamed. Newly acquired companies are included in the second year of consolidation, at the latest. If data of the business segments is not available in time, it is extrapolated on the basis of existing data. An adjustment will be made in the next report. Prior-year information was adjusted to conform to the current year's presentation. Due to rounding, individual numbers and percentages presented in this report may not precisely reflect the absolute figures.

<sup>2</sup> Data applies to hospital beds and water withdrawal in the business segment Fresenius Helios

<b>Waste Volumes</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
<b>Fresenius Kabi</b>					
Total waste volume, t	96,800	n.a.	n.a.	n.a.	n.a.
<i>thereof hazardous, %</i>	28	n.a.	n.a.	n.a.	n.a.
<i>recycling rate, %</i>	56	55	n.a.	n.a.	n.a.
<i>thereof non-hazardous, %</i>	72	n.a.	n.a.	n.a.	n.a.
<i>recycling rate, %</i>	72	68	n.a.	n.a.	n.a.
<b>Fresenius Helios</b>					
Total waste volume, t <sup>1</sup>	37,521	36,949	38,687	38,193	22,169
<i>thereof hazardous waste</i>	3,264	3,080	2,521	2,079	556
<i>thereof non-hazardous waste</i>	34,257	33,869	36,166	36,114	21,613
Hospital waste per bed <sup>1</sup> , in tons (t)	1.01	1.01	1.09	1.07	0.75
Hazardous hospital waste per bed <sup>1</sup> , in tons (t)	0.09	0.08	0.07	0.05	0.02

<sup>1</sup>Applies to all hospitals in Germany and Spain of Fresenius Helios; 2017 only Germany. Waste volumes extrapolated.

<b>Energy consumption</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
Group, in million MWh <sup>1</sup>	5.8	5.5	5.3	5.3	5.4
<i>Fresenius Medical Care</i>	2.6	2.5	2.4	2.4	2.8
<i>Fresenius Kabi</i>	1.8	1.7	1.6	1.7	1.6
<i>Fresenius Helios</i>	1.2	1.2	1.1	1.1	1.0
<i>Fresenius Vamed</i>	0.2	0.2	0.2	0.2	0.1
by source, in %					
<i>Gas consumption</i>	47	46	45	n.a.	n.a.
<i>Electricity consumption</i>	42	44	44	n.a.	n.a.
<i>Purchased heat, steam, cooling</i>	7	6	5	n.a.	n.a.
<i>Fossil fuels, excl. gas</i>	2	2	3	n.a.	n.a.
<i>Renewable energies</i>	2	2	2	n.a.	n.a.
<b>Fresenius Group<sup>1</sup> relative energy consumption</b>					
Energy consumption / € 1 million sales	156	151	150	159	167
Energy consumption / FTE	20.9	19.8	20.3	21.7	23.4
Energy consumption / hospital bed <sup>2</sup>	30.4	31.0	30.5	31.9	34.1



<sup>1</sup> Fresenius Medical Care figures include energy consumption at production sites, as well as electricity consumption at dialysis centers. The data from Fresenius Helios encompasses as of 2018 all hospitals in Spain and the clinics in Latin America as of 2020. Fresenius Vamed's data includes all fully consolidated health care facilities and service entities, and, as of 2018, the German post-acute care business transferred from Fresenius Helios to Fresenius Vamed. Newly acquired companies are included in the second year of consolidation, at the latest. If data of the business segments is not available in time, it is extrapolated on the basis of existing data. An adjustment will be made in the next report. Prior-year information was adjusted to conform to the current year's presentation. Due to rounding, individual numbers and percentages presented in this report may not precisely reflect the absolute figures

<sup>2</sup> Data applies to hospital beds in the business segment Fresenius Helios; 2017 only Germany

<b>Emissions (Scope 1 and 2)</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
<b>Group, t CO<sub>2</sub> equivalents in thou.<sup>1</sup></b>	1,524	1,512	1,504	1,534	n.a.
Scope 1	578	536	522	521	n.a.
Scope 2	946	976	982	1,013	n.a.

	<b>2021</b>	<b>2020</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>
Fresenius Medical Care	766	770	775	776	n.a.
<i>Scope 1</i>	263	242	227	219	n.a.
<i>Scope 2</i>	503	527	547	557	n.a.
Fresenius Kabi	443	417	409	424	422
<i>Scope 1</i>	170	160	169	169	174
<i>Scope 2</i>	273	256	239	255	248
Fresenius Helios	277	287	284	296	255
<i>Scope 1</i>	122	112	107	114	103
<i>Scope 2</i>	155	175	178	182	152
Fresenius Vamed	39	39	36	38	9
<i>Scope 1</i>	23	21	18	19	3
<i>Scope 2</i>	16	17	18	19	6

#### **Fresenius Group<sup>1</sup> relative GHG emissions scope 1 and 2**

t CO <sub>2</sub> equivalents / € 1 million sales	41	42	42	46	n.a.
t CO <sub>2</sub> equivalents / FTE	5.5	5.5	5.8	6.2	n.a.

<sup>1</sup> Fresenius Medical Care figures include energy consumption at production sites, as well as electricity consumption at dialysis centers. Emissions include Scope 1 and 2 emissions of production sites and Scope 2 emissions of in-center treatments in dialysis clinics. The data from Fresenius Helios encompasses as of 2018 all hospitals in Spain and the clinics in Latin America as of 2020. Fresenius Vamed's data includes all fully consolidated health care facilities and service entities, and, as of 2018, the German post-acute care business transferred from Fresenius Helios to Fresenius Vamed. Newly acquired companies are included in the second year of consolidation, at the latest. If data of the business segments is not available in time, it is extrapolated on the basis of existing data. An adjustment will be made in the next report. Prior-year information was adjusted to conform to the current year's presentation. Due to rounding, individual numbers and percentages presented in this report may not precisely reflect the absolute figures

**Note 1:** KPIs subject to the limited or reasonable assurance by the auditor are provided in the Fresenius Group Annual Report 2021. Other KPI are voluntarily reported in this overview or the Sustainability Online Report.

[Fresenius Group Annual Report 2021](#)

[Fresenius Group Online Sustainability Report 2021](#)

**Note 2:** Sustainability KPI for Fresenius Medical Care are published on the business segment's website, see:

[Fresenius Medical Care ESG Performance Data](#)